[
  {
    "ts": null,
    "headline": "Incyte: New CEO Brings A New Possible Outcome",
    "summary": "Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Find out why INCY stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=73dfb6a7238f4b61c6bd612c9d6c8df83af8f5992b45fb57b6d7b8869b4ca84a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751523077,
      "headline": "Incyte: New CEO Brings A New Possible Outcome",
      "id": 135727960,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1832921718/image_1832921718.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Find out why INCY stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=73dfb6a7238f4b61c6bd612c9d6c8df83af8f5992b45fb57b6d7b8869b4ca84a"
    }
  }
]